Navigation Links
Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:11/9/2012

NEW HAVEN, Conn., Nov. 9, 2012 /PRNewswire/ --Event:

HCV Connection Media BriefingDate:

Monday, November 12Time:

7:45 a.m. Eastern Standard TimeWhere:

Sheraton Boston Hotel; 39 Dalton Street, Boston, MA 02199; Also available by Webcast (link will be provided upon request)The content of the media briefing will include the following themes and information:

  • An overview of HCV and the current epidemic worldwide
  • A compelling historical and scientific context for understanding the new era of HCV therapies and the emergence of patient-guided therapy
  • A brief review of first and second-generation direct-acting antiviral therapies, including important new developments in drug discovery
  • A detailed look at Achillion Pharmaceutical's portfolio aimed at curing HCV in a complex and diverse patient population
  • Following the briefing there will be a Question & Answer session with leading experts in HCV including:

  • Fred Poordad, MD, Chief Medical Officer of the Texas Liver Institute and Alamo Medical Research, San Antonio, Texas
  • Andrew Muir, MD, Director, Gastroenterology and Hepatology Research Group, Duke Clinical Research Institute, Durham, North Carolina
  • The session will also be moderated by Lisa Stark of ABC News
  • Achillion (Nasdaq: ACHN) is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified and advanced multiple therapeutic compounds, many with novel mechanisms or attributes. Achillion is focused on solutions for the most challenging problems in infectious disease including hepatitis C (HCV) and resistant bacterial infections. Please visit www.achillion.com for additional information.


    '/>"/>
    SOURCE Achillion Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
    2. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
    3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
    4. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
    5. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    6. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
    7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
    8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
    9. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
    10. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
    11. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
    (Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
    (Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
    (Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
    (Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
    (Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
    Breaking Medicine News(10 mins):